cyrilzakka/clinical-trials huggingface dataset:
Intraperitoneal Paclitaxel Plus Systemic mFOLFOX6

Treatment for stage 4 gastric cancer with peritoneal carcinomatosis has been unchanged for decades. The median survival for stage 4 gastric cancer is 9-14 months with systemic chemotherapy. Intraperitoneal chemotherapy in combination with systemic chemotherapy is under many clinical trials mainly in Japan, and are showing promising results.

This is Korea's first clinical trial on Intraperitoneal Paclitaxel with Systemic mFOLFOX6 chemotherapy.


Eligibility Criteria:
Inclusion Criteria:

* Biopsy proven adenocarcinoma of gastric origin, primary or recurrent
* Identification of Peritoneal seeding by CT or diagnostic laparoscopy
* Patients confirmed to receive mFOLFOX6 on multidisciplinary outpatient clinic
* No previous history of chemotherapy or 4week after the last chemotherapy for gastric cancer
* Labs adequate for chemotherapy (within 2 weeks of enrollment)
* Absolute Neutrophil Count: ≧ 1,500/mm³
* Hemoglobin level: ≧ 8.0g/dL
* Platelet Count: ≧ 10×104/mm³
* AST (GOT), ALT (GPT): ≦ 100U/L
* Total Bilirubin: ≦ 2.0mg/dL
* Creatinine Clearance (CCl): ≧ 50mL/min
* ECOG 0 - 2
* Her-2 negative on endoscopic biopsy
* Age ≧ 20, \< 80
* Signed Informed consent form

Exclusion Criteria:

* Patients with other major medical disease or malignant tumors other than gastric cancer
* Contraindication to 5-FU, Oxaliplatin, Leukovorin or Paclitaxel
* Pregnant, breast-feeding women or with birth plan
* Patients refusing treatment
Validation of a Novel Non-invasive Continuous Blood Pressure Monitor in Children Ages 2- 17 Years-old

This is a prospective observational study to investigate if a non-invasive blood pressure monitoring device, the CareTaker Pulse Decomposition Analysis (PDA), can accurately measure blood pressure in children when compared to an arterial line. Enrolled patients will have the CareTaker PDA device placed on their finger during their operation to collect data for 30 minutes. Blood pressure readings from the CareTaker PDA device will be compared to measurements from the patient's indwelling arterial line, which will be placed as part of the patient's clinical care plan.


Eligibility Criteria:
Inclusion Criteria:

* Plan to receive an invasive arterial blood pressure monitor as part of their anesthesia care plan at the BCH Longwood campus

Exclusion Criteria:

* Patients with vascular or congenital heart disease known to affect large and small arteries
* Patients who declined to participate.
Vitamin C Supplementation Plus Hypoglycemic Agents Versus Hypoglycemic Agents Alone in Type 2 Diabetes Mellitus

Null hypothesis:

No significant effect of vitamin C 500 mg Supplementation on the severity of micro-vascular complications of type 2 Diabetes Mellitus (DM).

Alternative hypothesis:

There is a significant effect of vitamin C 500mg supplementation on the severity of the micro-vascular complications of type 2DM.


Eligibility Criteria:
Inclusion Criteria:

* clinical diagnosis of type 2DM
* patients in good health
* receiving oral hypoglycemic drugs

Exclusion Criteria:

* Insulin dependent diabetes
* receiving vitamin complex
* smoking
* renal disease
* liver disease
Study of the Use of Venetoclax in Participants With Chronic Lymphocytic Leukemia (CLL) Under Real-Life Setting

An observational study to assess the effectiveness, health economic-relevant costs and participant reported outcomes in participants with Chronic lymphocytic leukemia (CLL) receiving venetoclax as a monotherapy or in combination with rituximab or obinutuzumab as prescribed at the discretion of the physician and in accordance with local clinical practice and label.


Eligibility Criteria:
Inclusion Criteria:

* Participant with chronic lymphocytic leukemia (CLL) administering venetoclax and who meets the following conditions as specified in the label for venetoclax:
* Venetoclax monotherapy for the treatment of CLL in the presence of deletion chromosome 17 (del\[17p\]) or tumor protein p53 (TP53) mutation in adult participants, who are unsuitable for or have failed to a B-cell receptor pathway inhibitor.
* Venetoclax monotherapy for the treatment of CLL in the absence of del(17p) or TP53 mutation in adult participants, who have failed both chemoimmunotherapy and a B-cell receptor pathway inhibitor.
* Venetoclax in combination with rituximab for the treatment of adult participants with CLL who have received at least one prior therapy.
* Venetoclax in combination with obinutuzumab for previously untreated adult participants with CLL.

Exclusion Criteria:

- None
Correlation Between Respiratory Variability of R-R Intervals and Systolic Pressure Variability

This prospective study is designed to assess and quantify the correlation between respiratory changes in R-R interval and the respiratory changed in invasive systolic blood pressure in ventilated patients during changes in posture and peak end expiratory pressure (PEEP) and following a fluid bolus


Eligibility Criteria:
Inclusion Criteria:

* Age 18-80
* Scheduled for surgery under general anesthesia requiring invasive blood pressure monitoring

Exclusion Criteria:

* Heart Rate other than sinus
* Cardiac Pacemaker Status
* Transplanted Heart
The Effect of Creative Drama on the Level of Mental Health Literacy

This study was planned as a randomized controlled trial to determine the effect of creative drama education given to nursing students on mental health literacy scores

This studies designed experimentally. among the first-year students of nursing who cannot repeat the class, who have not received mental health literacy training before, and who are willing to participate in the study will form the group of the study. The designated group will be divided into experimental (creative drama) and control group (classroom training). Training to the experimental group will be applied to the control group through creative drama through in-f training. The trainings are planned as 4 sessions and each session/lesson is planned as 50+50 (100 minutes). As a measurement tool, the mental health literacy scale will be used as the pre-test and final test.

Eligibility Criteria:
Inclusion Criteria:

Have not received any training on mental health or mental health literacy, Have reached the age of 18 No more class repetition volunteer to participate in the study nursing students were included in the study

Exclusion Criteria:

Have received any training in mental health or mental health literacy, Under 18 years of age Remaining for class repetition who is not willing to participate in the study nursing students were not included in the study
The Safety and Effectiveness of Clarithromycin Plus Zidovudine or Dideoxyinosine in the Treatment of Mycobacterium Avium Complex (MAC) Infections in Children With AIDS

To evaluate three doses of clarithromycin in children with AIDS and Mycobacterium avium complex (MAC) infection who are receiving concurrent antiretroviral therapy.

Before more extensive evaluation of this promising drug for treatment of MAC infection in children can be done, it is important to study the pharmacokinetics of this drug in this population, to get information regarding its use in pediatric patients receiving currently available antiretroviral drugs, and to get information on the antimycobacterial activity of this drug.

Before more extensive evaluation of this promising drug for treatment of MAC infection in children can be done, it is important to study the pharmacokinetics of this drug in this population, to get information regarding its use in pediatric patients receiving currently available antiretroviral drugs, and to get information on the antimycobacterial activity of this drug.

Patients that are included are HIV infected and have started zidovudine (AZT) or didanosine (ddI) at least 4 weeks before entry into this study. Patients continue taking the medications at prescribed doses. In addition they also take clarithromycin. Patients continue treatment with AZT or ddI plus clarithromycin for 12 weeks.

Eligibility Criteria:
Inclusion Criteria

Concurrent Medication:

Allowed:

* Prophylaxis treatment for Pneumocystis carinii pneumonia.
* Topical antivirals.

Prior Medication: Required:

* Zidovudine (AZT), 90 - 180 mg/m2 q6h, or didanosine (ddI), 60 - 120 mg/m2 q8h for 4 weeks prior to study entry.

Patients must have the following:

* Diagnosis of AIDS and Mycobacterium avium complex.
* Ability to tolerate therapy with zidovudine or didanosine at specified dosages.
* Written consent from a parent or legal guardian.
* Willing to comply with all procedures and scheduled visits. Relatively stable clinical condition.

Exclusion Criteria

Co-existing Condition:

Patients with the following conditions or symptoms are excluded:

* History of significant depressive disorder.
* History of allergy to macrolide antibiotics.
* Presence of acute bacterial infection or acute onset of opportunistic infection as listed in protocol.

Patients with the following are excluded:

* Presence of current opportunistic infection other than Mycobacterium avium complex defined as systemic candidemia, cryptosporidiosis, isosporiasis, toxoplasmosis, pneumocystosis, salmonellosis, or acute bacterial infection.

Prior Medication:

Excluded within 30 days of study entry:

* Systemic antimycobacterial drugs, myelosuppressive drugs, nephrotoxic agents, cytotoxic or experimental chemotherapy, or antiviral drugs.

Active alcohol or drug use sufficient in the opinion of the investigator to prevent adequate compliance with medication regimen and clinic visits.
Virtual Reality on Pain and Fear Level During Kirschner Wires (K-Wires) Removal in Children

This study will be conducted to examine the effect of virtual reality applied during K-wire removal and dressing on the pain and fear levels that develop due to the procedure in children aged 7-12 years who apply to the orthopedic outpatient clinic.

Technology-based methods have now begun to be used to control anxiety and prevent pain that may occur before, during and after diagnosis and treatment procedures in children.

Virtual reality (VR), which is among the technological products, can be used in non-pharmacological methods as well as pharmacological methods.

It has been observed that VR, especially in children, creates an analgesic effect by mainly distracting the pain centers in the brain and evokes positive emotions with an anxiolytic effect.Since children do not want to see the procedures to be performed on them, virtual reality used during the procedure is one of the methods of diverting attention from the environment they are in. This study will be conducted to examine the effect of virtual reality applied during K-wire removal and dressing on the pain and fear levels that develop due to the procedure in children aged 7-12 years who apply to the orthopedic outpatient clinic.

Eligibility Criteria:
Inclusion Criteria:

* Being a child between the ages of 7-12 who will have the K wire removed
* The child is not using glasses
* The child must be at a cognitive development level that can respond to video selection.

Exclusion Criteria:

* Having a disease that causes chronic pain
* The child must have used medication that would have an analgesic effect in the last 24 hours before the application.
* The child is wearing glasses
* The child has a mental or neurological disability
Acute Kidney Injury Among Pediatric Cancer Patients At South Egypt Cancer Institute

Cancer is the second most frequent cause of premature death in children. The incidence of pediatric cancer varies by region and country, but it is generally considered rare with an estimated 300,000 new cases diagnosed worldwide. Acute kidney injury in pediatric cancer patients refers to the sudden and often temporary loss of renal function, which can lead to a variety of complications if not treated correctly.

* Primary: To determine the cumulative incidence of AKI using KDIGO criteria in pediatric patients with malignancy in South Egypt Cancer Institute (SECI)
* Secondary:

  1. Incidence of Hospital-acquired and community-acquired AKI
  2. Asses the risk factors of the incidence of AKI
  3. To determine in-hospital outcome (time to in-hospital death, length of hospital stay, and time to kidney recovery) of AKI.

This is a prospective study that will be carried out in the Paediatric Oncology and Haematological Malignancies Department including patients diagnosed with malignant tumours and hospitalized from 1st April 2023 for one year duration.

Eligibility Criteria:
Inclusion Criteria:

* • Children of both sexes (aged from 1 month to 18 years at diagnosis)

  * Patients with either hematological malignancies or solid tumors admitted to the Paediatric Oncology and Haematological Malignancies Department

Exclusion Criteria:

* Children who had an unconfirmed cancer diagnosis.
* Children more than 18 years at diagnosis.
* Children with preexisting chronic kidney disease (CKD) that defined as the presence of structural or functional kidney damage that persist over minimum of three month
* The patient underwent hematopoietic stem cell transplantation. Patients with 1 s.Cr level.
* Patient underwent renal transplant.
Olaparib in the Treatment of BRCA1/2 Unmutated and BRCA1 Promoter Methylated Recurrent and Metastatic Triple-negative Breast Cancer

This is an open-label, single-arm, single-center,exploratory clinical study.

This is an open-label, single-arm, single-center,exploratory clinical study initiated by the investigator to evaluate the efficacy of olaparib in recurrent and metastatic TNBC without BRCA1/2 mutation and methylated BRCA1 promoter.

Eligibility Criteria:
Inclusion Criteria:

* 1. Age 18-70 years old, female; 2. Histologically confirmed recurrent and metastatic TNBC patients without BRCA1/2 mutation and BRCA1 promoter methylation.

Note: Triple-negative breast cancer is defined as estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor (HER2) negative. ER and PR negative were defined as: ER\<1% positive, PR\<1% positive. HER2 negativity was defined as: HER2 (-) or (1+) or HER2 (2+) FISH negative by immunohistochemistry.

3. The number of treatment lines at the stage of recurrence and metastasis should not exceed 2 lines.

4. According to RECIST1.1 criteria, there is at least one evaluable lesion; 5. ECOG physical condition score ≤ 1 point; 6. Expected survival period ≥ 3 months;

Exclusion Criteria:

* 1. Pregnant, breastfeeding women, or those who are fertile and unwilling to take effective contraceptive measures; 2. Patients who have received chemotherapy, radiotherapy, targeted therapy and other anti-tumor treatments within 4 weeks before enrollment; 3. Previous use of PARP inhibitors, including olaparib and other PARP inhibitors; 4. Known serious cardiovascular disease, myocardial infarction, or arterial thrombosis, or unstable angina pectoris, or known heart failure in the past 6 months, QT interval\>450ms; 5. The toxicity of the previous treatment regimen has not recovered before enrollment, and there are still toxic reactions of grade 1 or above (except for alopecia); 6. Clinically obvious gastrointestinal abnormalities that may affect the intake, transport or absorption of drugs (such as inability to swallow, chronic diarrhea, intestinal obstruction, etc.) or patients with total gastrectomy; 7. Patients with known or suspected brain metastases, including central nervous system and spinal cord compression or meningeal metastases; 8. History of severe central nervous system disease (including epilepsy patients); 9. In the past 5 years, suffering from a second primary malignant tumor other than breast cancer and receiving related treatment; 10. Known congenital or acquired immunodeficiency, active hepatitis, active tuberculosis and other active infections; 11. Patients who are allergic to this test drug or similar drugs; 12. Those who have participated in clinical trials of other drugs within 28 days before screening, or plan to participate in any other clinical trials during this study; 13. Any other disease or condition of clinical significance (such as active or uncontrolled infection, etc.) that the investigator believes may affect compliance with the protocol or affect the patient's signing of ICF
Urinary Incontinence Awareness of Syrian Women

This study aimed to investigate the UI knowledge, attitudes, and awareness of Syrian females under temporary protection status in Turkey and compare it with Turkish females. Establishing societal standards surrounding urinary incontinence beliefs and attitudes can alter societal approaches to urinary incontinence. Early diagnosis and treatment can reduce the financial burden when urinary incontinence ceases to be an issue that needs to be hidden. Additionally, as females become more aware of urinary incontinence, urinary incontinence symptoms, urinary incontinence prevention, and treatment approaches, the number of patients receiving help for incontinence will increase.

This study explores the knowledge, attitudes, and awareness of urinary incontinence (UI) among Syrian women under temporary protection in Turkey, compared to Turkish women. Involving 327 participants (186 Turkish, 141 Syrian), the study assesses sociodemographic data, gynecological and incontinence-related questions, and the Urinary Incontinence Awareness and Attitude Scale (URINAS). The study underscores the impact of sociocultural and economic factors on gender-specific health disorders, especially among refugees, and emphasizes the need for culture-specific interventions to enhance UI awareness among immigrant women. The findings can offer valuable insights for developing health policies and awareness programs aimed at improving UI management and reducing the stigma associated with it.

Eligibility Criteria:
Inclusion Criteria:

* being over 18 years of age
* volunteer for participation
* be under temporary protection

Exclusion Criteria:

* illiteracy
* any neurological disease that would affect cooperation
Intracoronary Adenosine Administration to Prevent Periprocedural Myonecrosis in Elective Coronary Angioplasty

Aim of the study is to evaluate the benefits from adjunctive intracoronary administration of adenosin in elective patients undergoing coronary angioplasty.

This study will investigate the effects of adjunctive intracoronary administration of adenosine on periprocedural myocardial infarction as compared to placebo.

This is a double-blind randomized trial single-center study. The enrollment will last 10 months.

Eligibility Criteria:
Inclusion Criteria:

* Patients undergoing elective coronary angioplasty

Exclusion Criteria:

Marked Bradycardia (\< 40 bpm)

* Previous allergy to adenosine
* Inability to sign the informed consent
* Asthma
* Elevated cardiac enzymes (troponin I o CK-MB)
Propofol or Midazolam for Sedation and Early Extubation Following Coronary Artery Bypass Graft Surgery

Propofol and midazolam are used frequently as sedating agents among patients who undergo coronary artery bypass graft surgery but no study in Pakistan has been done to compare their effectiveness aiming early extubation.

Propofol is an intra lipid and alkali phenol chemically it is unrelated to sedative agents or anaesthetic. Midazolam is a banzodiazepen. Most of its properties are similar to diazepam. It is a common practice to use sedatives to provide comfort and decrease "ventilator-asynchrony" in critically ill patients that may require prolonged invasive mechanical ventilation. The other reason to employ sedatives is to reduce the anxiety associated with the inaviseve procedures routinely conducted in the ICU.

Eligibility Criteria:
Inclusion Criteria:

* Patients of American Society of Anesthesiologists (ASA) III who were selected for coronary artery bypass graft surgery.

Exclusion Criteria:

* History of any psychiatric disease.
* Using antidepressants
* Alcohol abusers
* Obese
* Pregnant women
Effect of Kinesio Taping on Upper Extremity Performance in Individuals With Rounded Shoulders

The objective of this research is to study the effect of kinesio tapes with functional correction technique in combination with exercise management to increase strength and decrease pain, in people with rounded shoulders. The study would be evaluated with the EvaltechTM machine, (functional capacity assessment).

Participants

* Age 25-50 years, male and female
* People who have a shoulder condition. (By measuring in the supine position, distance from the posterior aspect of acromion to the bed\> 1 inch on both sides)
* People with moderate to severe neck and shoulder pain (VAS\> 3)
* People who have to use their arms for work Overall more than 3 hours per day

For attaching the tape, the researcher will prepare a replacement shirt in case the For the convenience of tape, the experimental group, trained by Certified Kinesio tape, attached the kinesio tape. Attaching the tape By using functional correction techniques, apply from the front of the acromion process to the spinous process T10 on both sides.

Measurements

1. The pressure of (average of peak force) of both arms (pounds)
2. The pulling force (average of peak force) of both arms (pounds)
3. Time of overhead endurance test (TMT) (seconds)
4. Visual analog scale (VAS)
5. The distance from the posterior aspect of acromion to the bed (inches)

process of measuring the evaluation 3 times

1. st after physical therapy treatment Before attaching the kinase tape
2. nd evaluation period was 48 hours apart before the next treatment.
3. rd evaluation period is 1 week apart.

Eligibility Criteria:
Inclusion Criteria:

* Age 25-50 years, male and female
* People who have a shoulder condition. (By measuring in the supine position, distance from the posterior aspect of acromion to the bed\> 1 inch on both sides)
* People with moderate to severe neck and shoulder pain (VAS\> 3)
* People who have to use their arms for work Overall more than 3 hours per day

Exclusion Criteria:

* People with neck pain, fracture in the arm, and numbness
* People who have pain and have limited shoulder movement of the shoulder joint
* People who have had a history of spine / shoulder surgery
* People with a history of allergies to cloth tapes
* People who have rheumatoid arthritis that affects inflammation of the joints such as rheumatoid etc.
* People receiving medication that affects their participation in the study
* People with neurological symptoms
* People with cognitive disabilities
A Study To Determine If Two Different Versions Of Topotecan Have The Same Potency In Patients With Advanced Solid Tumors

The purpose of this study is to determine the bioequivalence of the new oral capsule formulation to the currently used oral capsule formulation of topotecan.


Eligibility Criteria:
Inclusion Criteria:

* Subjects with advanced solid tumors.
* At least 4 weeks since last chemotherapy, radiotherapy, biologic therapy or surgery.
* Subjects must be free of post-treatment side effects.

Exclusion Criteria:

* Women who are pregnant or lactating
* Subjects with uncontrolled emesis, regardless of etiology, active infection.